Compare STLA & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STLA | TEVA |
|---|---|---|
| Founded | 2021 | 1901 |
| Country | Netherlands | Israel |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7B | 30.2B |
| IPO Year | N/A | N/A |
| Metric | STLA | TEVA |
|---|---|---|
| Price | $9.73 | $31.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $12.49 | ★ $32.67 |
| AVG Volume (30 Days) | ★ 12.5M | 8.3M |
| Earning Date | 02-25-2026 | 01-28-2026 |
| Dividend Yield | ★ 5.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.62 |
| Revenue | ★ $171,605,402,237.00 | $16,776,000,000.00 |
| Revenue This Year | $0.20 | $4.62 |
| Revenue Next Year | $5.45 | $0.34 |
| P/E Ratio | ★ N/A | $51.55 |
| Revenue Growth | N/A | ★ 0.02 |
| 52 Week Low | $8.39 | $12.47 |
| 52 Week High | $14.28 | $33.42 |
| Indicator | STLA | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 36.99 | 59.53 |
| Support Level | $9.32 | $30.70 |
| Resistance Level | $11.32 | $32.86 |
| Average True Range (ATR) | 0.26 | 0.79 |
| MACD | -0.11 | -0.28 |
| Stochastic Oscillator | 19.95 | 45.90 |
Stellantis was created out of the merger of US-based Fiat Chrysler Automobiles and French-based Peugeot in January 2021, resulting in the fourth-largest automotive original equipment manufacturer by vehicle sales. In 2024 it sold 5.5 million vehicles, 47%, 26% and 17% in Europe, North America, and South America, respectively. Its brands include Fiat, Jeep, Chrysler, Ram, Peugeot, Citroën, Opel, Alfa Romeo, and Maserati.
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.